The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | An update to the risk stratification of MGUS, SMM, and multiple myeloma
Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN, discusses the updated risk stratification for the diagnosis and management of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). Recent changes include incorporating dynamic alterations into MGUS stratification and adding cytogenetics to SMM risk assessment. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
